NCT07093970View on ClinicalTrials.gov

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

MRG006A

Administrated intravenously

Trial Locations (2)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY